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Experimental autoimmune encephalomyelitisB cells, plasma cells, and antibodies are commonly found in active central nervous system (CNS) lesions in
patients with multiple sclerosis (MS). B cells isolated from CNS lesions as well as from the cerebrospinal ﬂuid
(CSF) show signs of clonal expansion and hypermutation, suggesting their local activation. Plasma blasts and
plasma cells maturating from these B cells were recently identiﬁed to contribute to the development of
oligoclonal antibodies produced within the CSF, which remain a diagnostic hallmark ﬁnding in MS. Within
the CNS, antibody deposition is associated with complement activation and demyelination, indicating
antigen recognition-associated effector function. While some studies indeed implied a disease-intrinsic and
possibly pathogenic role of antibodies directed against components of the myelin sheath, no unequivocal
results on a decisive target antigen within the CNS persisted to date. The notion of a pathogenic role for
antibodies in MS is nevertheless empirically supported by the clinical beneﬁt of plasma exchange in patients
with histologic signs of antibody deposition within the CNS. Further, such evidence derives from the animal
model of MS, experimental autoimmune encephalomyelitis (EAE). In transgenic mice endogenously
producing myelin-speciﬁc antibodies, EAE severity was substantially increased accompanied by enhanced
CNS demyelination. Further, genetic engineering in mice adding T cells that recognize the same myelin
antigen resulted in spontaneous EAE development, indicating that the coexistence of myelin-speciﬁc B cells,
T cells, and antibodies was sufﬁcient to trigger CNS autoimmune disease. In conclusion, various pathological,
clinical, immunological, and experimental ﬁndings collectively indicate a pathogenic role of antibodies in MS,
whereas several conceptual challenges, above all uncovering potential target antigens of the antibody
response within the CNS, remain to be overcome.chnische Universität München,
49 89 4140 4601; fax: +49 89
mmer).
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For decades, self-reactive antibodies have been implicated to
participate in the pathogenesis of multiple sclerosis (MS). Increased
immunoglobulin (Ig) levels in the cerebrospinal ﬂuid (CSF), ﬁrst
described to be suggestive for MS in 1942 by Kabat et al. [1], remain a
hallmark ﬁnding in the diagnosis of disease. Since then, a plethora of
investigations attempted to identify the target antigens which these
antibodies may be raised against. Some ﬁndings implicated that
antibodies within the inﬂamed CNS may eventually recognize
components of the myelin sheath; however, no unequivocal evidence
of such CNS reactivity has been established to date. While the
occurrence of antibodies in the CSF is thus tightly associated with the
diagnosis of MS, it is still under debate whether these newly occurring
Ig indeed actively contribute to pathogenesis or progression of the
disease. In this review, we will present a variety of pathological and
immunological ﬁndings supporting a pathogenic role of humoral
immune responses in MS. Further, we will provide an overview on therole of antibodies in the animal model experimental autoimmune
encephalomyelitis (EAE) and discuss applicability and implication of
these experimental ﬁndings to human CNS demyelinating inﬂamma-
tory disease.
2. The role of antibodies in central nervous system autoimmune
disease—evidence from human studies
2.1. Antibodies in the central nervous system
Strong evidence for a role of antibodies in MS derives from
histopathological studies in which B cells, as well as B-cell-derived
plasma cells and antibodies, are found in the central nervous system
(CNS). Of importance, molecular analyses of B cells in brain lesions
demonstrate an accumulation of clonotypic B cells with preferential use
of particular variable (V) heavy (H) chain (VH) genes indicating a
restricted local immune response. Furthermore, investigated sequences
showed signs of hypermutations reﬂecting an ongoing and maturating
B-cell response to the target antigen [2–4]. After antigen challenge, B
cells mature to short-lived plasma blasts and plasma cells, both subsets
produce large amount of antibodies. Antibodies are frequently observed
in acute lesions of MS patients. In newly diagnosed patients,
histopathological studies demonstrate heterogeneity of acute lesions
240 M.S. Weber et al. / Biochimica et Biophysica Acta 1812 (2011) 239–245between individual patients suggesting at least four distinct patterns of
acute demyelinating lesions exist [5,6]. The most frequent pattern is
characterized by signiﬁcant antibody deposits and complement
activation. In contrast, in acute lesions of patients with established
MS, a more homogenous pattern was observed [7]. Whereas it can be
questioned whether these specimen are entirely representative for
established disease, all samples tested contained antibodies and
complement deposition [7]. Complement activation supports the role
of pathogenetic antibodies and antibody-mediated effector functions
and is found in areas of demyelination [5,8].
The CSF compartment gives also evidence for a role of antibodies in
MS. About 50–60% of all diagnosed MS patients exhibit an intrathecal
production of IgG. After separation of CSF Ig by electrophoresis, this
IgG fraction appears as oligoclonal IgG bands (OCBs) in the CSF but not
in serumwhere IgG is polyclonal. OCBs extracted from the CNS have a
similar pattern as from CSF of the same individuals strengthening the
view that the CSF compartment reﬂects—at least partially—the milieu
in the CNS itself. The occurrence of such OCBs in CSF is still the only
reliable immunological test supporting clinical and MRI ﬁndings in
establishing the diagnosis of MS. The oligoclonal IgG pattern reﬂects
local accumulation of restricted IgG speciﬁcities and is concomitant
with a restricted Ig receptor repertoire in CSF. B cells, mostly IgM−/
IgD− memory cells, and plasma blasts are present in the CSF [9].
Interestingly, patients largely differ with respect to the presence of B
cells and plasma blasts in CSF [10]. The presence of plasma blasts
correlates with acute parenchymal inﬂammation as determined by
MRI [11]. Moreover, in infectious diseases, plasma blast numbers
correlate with the viral or bacterial load in the CSF [12,13], suggesting
that the presence of these cells reﬂects acute inﬂammatory activity.
Analysis of theH and L chain of B cells, plasma cells, and plasmablast
in the CSF ofMS patients revealed a restricted use of H and L chainswith
hypermutations in the variable region indicating a focused and ongoing
immune response in the CSF ofMS patients [14–18] similar towhatwas
observed in brain tissue. The relevance of CSF plasma blasts and plasma
cells [19], in the production of OCBs, had been for a long time an open
question. In a recent study, Obermeier et al. [20] compared the IgG
proteome in CSF and the IgG transcriptome from the B cellular
compartment in CSF and foundanoverlapbetweenboth compartments.
Furthermore, von Budingen et al. [21] found the same amino acid
sequences of H-CDR3 in clonally expanded plasma cells as well as in
OCBs using anti-idiotypic antibodies raised against the CDR region.
Interestingly, the OCBs, B-cell numbers, and B-cell clonotypes are stable
over years in the CSF of MS patients [11,22,23].
Hence, researchers have investigated the relevance of OCBs as
potential biomarkers for clinical outcome of patients with MS. OCB-
negative MS patients seem to have a more benign disease course [24].
Also, the number of OCBs and the intrathecal IgG synthesis [25]
correlated with a more progressive outcome in a retrospective
study [26] but not in a more recent study [27]. The presence of IgM
OCBs predicts a higher probability for conversion to secondary
progressive MS (SP-MS) [28] and intrathecal IgM production predicts
a higher progression rate [29]. However, this was not conﬁrmed by an
independent study [30].
2.2. Targets of antibodies in multiple sclerosis
OCBs are not speciﬁc for MS but are also found in other neuro-
immunological CNS diseases like neuroborreliosis, herpes simplex
encephalitis, human immunodeﬁciency virus (HIV) of the CNS, or
subacute sclerosing panencephalitis (SSPE). In infectious CNS dis-
eases, the OCBs speciﬁcally recognize the disease-causing antigens
[31,32].
Although researchers have been searching for the targets of the local
immune response in MS for many years, the target antigens of the
humoral immune response in MS are still largely unknown. MS lesions
are focused on CNS white matter, so that possible antigenic structureswhere suspected to be within this region. Whereas some data suggest
that lipids or carbohydratesmay be targets of the humoral response, the
main body of research provided evidence that the relevant components
may be proteins of the myelin sheath, such as myelin basic protein
(MBP), myelin oligodendrocyte glycoprotein (MOG), and proteolipid
protein (PLP). The immune response against myelin proteins has been
extensively investigated. However, to date, controversial results have
been obtained. In MS lesions, antibodies to myelin, especially MOG,
were found by immunohistochemical analysis [33] and IgGs extracted
from inﬂamed CNS also recognized MOG [34]. Elevated antibody titers
against MBP and/or MOG were also reported in serum and CSF of MS
patients [35–37] and in serum of children with the ﬁrst episode of CNS
demyelination [38,39]. Myelin-speciﬁc antibodies are, however, not
conﬁned to MS. They are also found in different neurological diseases
and even in healthy controls [40–42]. Moreover, a recent careful study
withantibodies reconstructed fromB-cell clonotypes fromtheCSFofMS
patients did not provide any evidence for binding of these antibodies to
MOG, PLP, or MBP.
In serum, anti-MOG and -MBP IgM antibodies determined by
immunoblot were reported to predict conversion toMS in CIS patients
[43]. Unfortunately this ﬁnding was not conﬁrmed by others [44,45].
Although antibody reactivities would be attractive for use as
biomarkers to predict relapses or progression to MS, no antibody
that is speciﬁc toMS has been yet identiﬁed. Thismay be in part due to
shortcomings in the assays to determine antibody responses to CNS
proteins. Especially membrane proteins are highly folded, and the
conformational epitope targets of autoantibodies. The conformational
epitopes are, however, not preserved in conventional assays such as
ELISA or Western blot. This problem was recently overcome by cell-
based assays. Using these assays, in which MOG is expressed by a
transfected cell line, serum antibodies to native MOG were observed
in a subgroup of patients [46,47]. Interestingly, high antibody titers
to native MOG were recently reported in two independent studies
in pediatric CIS, ADEM, and MS [48,49]. The use of whole myelin
particles also revealed a more frequent positive reactivity in MS and
CIS patients [50].
Furthermore, MS is very heterogenous with respect to histopath-
ological changes [5], CSF phenotype [10], disease course [51], and
response to therapy [52]. Accordingly, different mechanismsmay play
a role in demyelination. Not all patients might have a prominent
antibody response, or speciﬁc autoantibodies may characterize
distinct clinical entities.
In neuromyelitis optica (NMO), an autoantibody speciﬁc for
aquaporin-4 (Aqp-4), a water channel protein, was recently found
[53,54]. There is accumulating evidence that NMO is pathologically
different from MS and represents a distinct disease entity [55].
Transfer experiments have demonstrated that the Aqp-4 antibody can
induce astrocyte pathology upon transfer in animals after disruption
of the blood–brain barrier [56,57]. Such an astrocyte pathology is also
observed in patients with NMO [58]. In addition, the Aqp-4 antibody
titer seems to correlate with disease activity, further supporting the
concept that Aqp-4 is a major target of the autoimmune reponse in
NMO.
Besides the autoimmune hypothesis, it is assumed that infectious
agents may play a signiﬁcant role in the pathogenesis of MS. The
antibody reactivities against various numbers of pathogens have been
investigated in CSF and serum of MS patients (summarized in Gilden
[59]).Most discussedare Epstein–Barr virus (EBV), humanherpes virus-
6 (HHV-6), varicella zoster virus (VZV), and Chlamydia pneumoniae. The
hypothesis is still attractive in view of other infectious diseases of the
CNS, which cause inﬂammation and demyelination in humans such as
SSPE- or HTLV-I-associated myelopathy [60]. In these disorders, a
comparable chronic immune response is observed in the CNS, including
theoccurrence ofOCBs. Interestingly, the intrathecal Ig response and the
OCBs contain antibodies speciﬁc for the causative agent [61]. Similar to
autoantibody studies, many researchers have reported on elevated
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most ﬁndings were not conﬁrmed by independent studies. Only in EBV
that conclusive data on an increased antibody response were reported.
Since CNS resident proteins might be the target of the antibody
response, cDNA expression libraries generated from MS brain lesions
were developed and probed with CSF antibodies with little success
[62]. Phage display libraries containing random short peptides or
peptides derived from MS brain plaques were constructed and
displayed on phage surface-enabled large-scale screening of CSF
antibodies for identiﬁcation of binding epitopes orminotopes [63–67].
Using this technology, one group identiﬁed a 5-amino acid consensus
sequence present in Epstein–Barr virus nuclear antigen and a heat
shock protein, alphaB crystallin [65]. Recently, another group
identiﬁed antibodies to eight novel antigenic targets present in a
subgroup of MS patients but not in controls [67]. Using a human brain
cDNA expression library combinedwith epitopemapping, Cepok et al.
[68] identiﬁed two different EBV proteins, the well-known EBNA-1
and a novel protein BRRF-2, as putative targets of the oligoclonal
immune response in MS.
Recently, monoclonal recombinant antibodies (rAbs) were gener-
ated from clonally expanded and thereforemost likely disease-relevant
CSF IgG-secreting plasma cells and B cells of MS patients. This strategy
allows to produce an unlimited amount of relevant Igs for large-scale
screening of antibody binding using various antigens and tissues
[21,69,70]. Immunoﬂuorescent staining of MS lesions tissue with rAb
revealed reactivity to areas of myelin degradation [21] or axons [71].
However, speciﬁc reactivity of rAB to myelin epitopes could not be
conﬁrmed by immunostaining ofMOG-,MBP-, and PLP-transfected cell
lines or immunostaining of brain tissue sections [69]. Screening of rAB
reactivities to a larger number of different antigens, cells, and tissues
will be the next step to determine the speciﬁcity of these rAbs.
2.3. Effector mechanisms of antibodies in multiple sclerosis
Beside the prevalence of speciﬁc antibodies in MS, it will be crucial
to demonstrate a biological consequence of antibodies and their
participation in one effector function leading to demyelination. In
general, antibodies may exert their effector function through various
mechanisms.
1. A mechanism called antibody-dependent cellular cytotoxicity
(ADCC) in which cells of the innate immune system, e.g., NK cells
recognize and bind the gamma chain of the antigen-bound antibody
complex through the Fc-gamma receptor expressed on the effector
cell. The binding leads to the release of inﬂammatory components by
the effector cell mediating cytotoxicity and lysis of the target. Cell
lines transfected with the candidate antigen are an appropriate tool
for the measurement of antigen-speciﬁc ADCC [46,69].
2. Opsonization and phagocytosis is an additional effector mechanism of
antibodies. Here, antibodies speciﬁcally bind andopsonize the antigen,
e.g., myelin for recognition through the Fc-gamma receptor expressed
on phagocytotic cells like macrophages leading to the phagocytosis of
the antigen–antibody complex and destruction of the tissue. In MS
lesions and EAE brain tissue, phagocytotic cells containing Ig and
myelin proteins have been found [33], supporting the hypothesis of
cell-induced demyelination.
3. Complement activation by binding to antibodies is an additional
possible mechanism leading to demyelination. In this pathway,
complement components bind to structures of antibodies leading
to activation of the complement cascade and the assembly of the
membrane attack complex and destruction of the target [72].
Complement deposition was found in several studies associated
with macrophages in acute demyelinating lesions, suggesting an
antibody- and complement-mediated demyelination [7,8]. CSF IgG of
MSpatients containmainly IgG1 and IgG3. Both subclasses are potent
in the activation of the complement cascade. The potential fordemyelination by binding of antibodies against MOG and MBP was
shown to be related to the ability to ﬁx complement [73].
4. Beside the activation of effector cells or complement pathway the
antibodybinding itselfmightbeable to inducedemyelination.Martaet
al. investigated the signalling of anti-MOG antibody binding to MOG
and found that crosslinking of anti-MOG–MOG complexes resulted in
the phosphorylation of speciﬁc proteins related to cellular stress
response and cytoskeletal stability providing a possible biochemical
mechanism of antibody induced demyelination [74,75]. Antibodies
were also shown to modulate synaptic transmission [76].
5. Finally, antibodies have the capacity to neutralize antigens, mostly
relevant in neutralisation of circulating pathogens. In this mech-
anism, antibodies prevent by antigen opsonization the ability of
pathogen to spread and disturb cells of the host.
6. Furthermore, the pathogenicity of antibodies can be investigated
by transfer of human serum to animal disease models. Likewise,
serum from patients with high anti-MOG antibody titers stained
white matter myelin in rat brain and enhanced demyelination as
well as axonal damage when transferred to animals with ongoing
EAE [46]. Typical NMO-like lesion formation was observed in EAE
after transfer of human anti-Aqp-4-positive serum [57].
2.4. Evidence from therapeutic approaches in multiple sclerosis
B-cell-derived antibodies against CNS autoantigenmaybe important
in the pathogenesis of certain MS subtypes [3,15,35,77]. Based on this
assumption, plasma exchange has evolved as a therapeutic strategy to
remove or reduce self-reactive antibodies in treatment of acute MS
relapses. In a small observational study in patients with severe optic
neuritis refractory to conventional pulsed steroid therapy, plasma
exchange was associated with an improvement of visual acuity in 7 out
of 10 patients [78]. Another clinical trial investigated plasma exchange
in patients with recently acquired severe neurological deﬁcits from
attacks of inﬂammatory demyelinating disease, who failed to recover
after treatment with intravenous corticosteroids. Substantial clinical
improvement in neurological disability was observed in 42.1% of active
treatment courses comparedwith 5.9% in sham treatment [79]. A larger
trial dating back to 1989 also studied the effectiveness of plasma
exchange in acute MS exacerbations. In this trial, 116 patients were
assigned to receive 11 treatment cycles of plasma exchange or sham
exchange during 8 weeks. In addition, both groups received corticotro-
pin (ACTH) and cyclophosphamide. During the treatment period,
patients receiving plasma exchange clinically improved, whereas no
clear long-term beneﬁt was observed. Interestingly, the respective MS
subtype appears to be a predictor for the achievable beneﬁt fromplasma
exchange. In a recent clinical trialwithMS patients undergoing an acute
relapse, therapy-responsive patients could be identiﬁed to be histo-
pathologically deﬁned by antibody deposition and enrichment of B cells
within the CNS [80,81]. First, these data demonstrate the urge for
intravital biomarkers distinguishing individual MS subtypes. Second,
although it needs to be noted that all patients included did not
respond to initial steroid treatment, which may cause a bias towards
patients with severe relapses, this ﬁnding strongly supports that in a
subgroup of patients CNS-directed autoantibodies indeed contribute to
MS pathogenesis.
Another approach that may indirectly decrease titers of self-
reactive antibodies is therapeutic depletion of CD20-positive B cells.
Anti-CD20 (rituximab, Rituxan®)was initially developed to treat non-
Hodgkins B-cell lymphoma and has shown promising results in
treatment of CNS demyelinating diseases. In a small open-label pilot
study evaluating B-cell depletion in neuromyelitis optica (NMO), seven
out of eight patients receiving rituximab experienced substantial
improvement of neurologic function over 1 year [82]. In relapsing–
remittingMS, a recent placebo-controlled phase II trial revealed thatMS
patient receiving rituximab exerted a substantial reduction in develop-
ment of newly emerging inﬂammatory brain lesions. Despite the short
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clinical attack frequency [83]. Mechanistically, it remains to be
elucidated elimination of which B-cell function may correlate best
with apotential beneﬁt of B-cell depletion inCNSautoimmunedisease. It
can be speculated that rituximab immediately abolishes cellular B-cell
functions, such as B-cell antigen presentation, whereas myelin-speciﬁc
antibody titers appear to decrease with a substantial delay because
antibody-secreting plasma cells no longer express CD20. Based on this
assumption, it appears likely that the immediate beneﬁt of B-cell
depletion in T-cell-mediated autoimmune disease may indeed relate to
an impaired activation of T cells. In this regard, a recent study
demonstrated that in MS, anti-CD20 mediated depletion of B cells was
correlated with an altered response of T cells to unspeciﬁc activation
[84]. An experimental study revealed that activation and proinﬂamma-
tory differentiation of autoreactive T cells are impaired in the absence of
myelin-activated B cells [85]. Detailed longitudinal studies are about to
more thoroughly investigate the impact of B-cell depletion on T-cell
activation and whether a later decrease in self-reactive antibody titers
may contribute to long-term clinical stabilization of patients receiving
anti-CD20 therapy.
3. The role of antibodies in central nervous system autoimmune
disease—implications from animal models
The animal model of MS, EAE, is thought to be predominantly
mediated by pro-inﬂammatory, self-reactive T cells [86]. Strong
evidence for this assumption derives from the fact that adoptive
transfer of encephalitogenic T cells is sufﬁcient to induce EAE in
susceptible mice [87] and that EAE can be actively induced in B-cell-
deﬁcient mice [88]. Nevertheless, in addition to inﬁltrating T cells and
macrophages, B cells, plasma cells, and antibodies are found in areas of
myelin breakdown in EAE similar to active CNS lesions in some MS
patients [33,89,90]. Whereas it is clear that these antibodies alone are
not capable of initiating inﬂammation in brain and spinal cord, certain
EAE studies suggest that they might facilitate CNS damage and
promote disease progression.
3.1. Autoreactive antibodies in EAE—pathogenic involvement or
epiphenomenon?
Whereas MS is likely to be a heterogenous disease with differential
involvement of inﬂammation throughout its progression, autoimmune
T- and B-cell responses against CNS antigens remain a central
component in the current view of MS pathogenesis. Myelin antigens
are the prevalent putative targets studied in the ﬁeld due to the often
primarily demyelinating nature of inﬂammatory CNS lesions. Within
candidate myelin antigens, MOG is probably the one that is most
investigated due to its extracellular location on the outermost myelin
lamellae, which makes it an exposed target accessible to an initial
autoimmune attack against properly myelinated axons. The full-length
MOG protein is constituted of 218 amino acids and is exclusively
expressed within the CNS. Most importantly, MOG is highly encepha-
litogenic in the murine as well as in the marmoset EAE model.
Regarding the possible contribution of myelin-reactive antibodies to
EAE pathogenesis Schluesener et al. [91] reported more than 20 years
ago that a monoclonal antibody directed against MOG exacerbated
clinical and histological EAE in a rodent disease model. The authors
demonstrated convincingly that the intravenous administration of this
myelin-reactive antibody enhanced CNS demyelination and induced
fatal relapses in recipient mice. Notwithstanding this seminal observa-
tion, it appears necessary to benoted that the antibodywas injected into
already EAE-diseased mice at a quantity that is unlikely to be produced
endogenously. Experiments in B-cell-deﬁcientmice indicate indeed that
B cells or antibodies arenot requiredwhen the short encephalitogenic T-
cell-determinant peptide (p)35–55 is used to immunize mice in an
active EAE induction protocol [92]. A crucial step in disease induction byactive immunization is the presentation of the administered CNS
autoantigen to naïve encephalitogenic T cells by antigen-presenting
cells (APC) in the context of major histocompatibility complex (MHC)
class II. Short peptides, such as MOG p35–55, are known to be most
efﬁciently phagocytized and presented by dendritic cells and macro-
phages [93,94], so that B-cell encounter with the peptide antigen rarely
occurs. This results in twokey features of thismodel of CNS autoimmune
disease: B-cell antigen presentation does not play a crucial role for EAE
induction byMOGpeptide and low anti-MOG antibody titers, if any, are
generated.
B cells and antibodies may however be required for EAE induced by
the recombinant (r) extracellular domain of MOG, as genetically B-cell-
deﬁcient mice were found to be resistant to active immunization with
human rMOG [88]. Reconstitutionwith the antigen-speciﬁc antibodywas
sufﬁcient to restore EAE susceptibility, suggesting a crucial role for
antibody-mediated antigen recognition in thismodel [92]. Unfortunately,
the question whether B cells are required for MOG protein-induced EAE
appears to bemore complex though and is still debated lively. Oliver et al.
[95] reported that immunization with either rat or human MOG leads to
comparable titers of anti-MOGantibodies. However, only human (but not
rat) MOG was reported to induce a B-cell-dependent EAE model as
evaluated by active immunization of B-cell-deﬁcient mice. The sequence
of human MOG differs from rat MOG only at a few residues, including a
proline for serine substitution at position 42, which encodes within the
dominant T-cell determinant of MOG p35–55. Substituting this amino
acid with serine in human MOG p35-55 (resulting in the rat MOG
sequence) substantially increased its encephalitogenicity [95]. Further,
exchanging the same residue within human MOG protein appears to be
sufﬁcient to restore EAE susceptibility in B-cell-deﬁcient mice [72],
suggesting that B cells or B-cell-derived products are speciﬁcally required
to recognize human MOG protein due to the presence of proline at
position 42 within the three-dimensional protein.
Further, not all MOG-speciﬁc antibody responses are thought to be
pathogenic which can be determined by their antigen recognition. In
general, pathogenic MOG-speciﬁc antibodies recognize conformation-
dependentMOGepitopes that are only availablewithin the intact protein.
Antibodies that are speciﬁc for linear determinants, although they may
recognize antigens following tissue injury, are not thought to contribute
to disease initiation in a pathogenic manner [96–98]. Further, in EAE it
appears that immunization with either rat or human MOG leads to a
considerable development of anti-MOG antibodies, whereas only
immunizationwithhumanrMOGgenerates apathogenic, EAE-enhancing
MOG antibody response [74]. The gold standard to prove potential
antibody pathogenicity has become a cell-based assay, in which MOG is
expressed by a transfected cell line [46,47]. Throughmeasurement of cell
lysis, these assays allow determining whether antibodies are capable to
target conformationally folded, cell membrane-embedded MOG. Using
this technique, one study was able to demonstrate higher IgG antibody
titers to native MOG in the serum of MS patients comparedwith non-MS
control groups [46]. Most intriguingly, serum from patients with high
anti-MOG antibody titers stained white matter myelin in rat brain and
enhanceddemyelinationandaxonaldamagewhentransferred toanimals
with ongoing EAE. Along the same lines, a transgenic mouse engineered
to express the rearranged heavy chain of a pathogenic antibody
recognizing a conformational determinant of MOG (8.18-C.5) developed
more severe EAE with greater inﬂammation and demyelination com-
pared with wild-type mice [99]. Following a physiological B-cell
development, the MOG-recognizing antibody was expressed in these
mice as membrane-bound B-cell receptor as well as secreted by B-cell-
derived plasma cells. The combination of the fact that serum from these
mice bound speciﬁcally to native, brain-derived MOG and the observed
enhancement of CNS demyelination these studies may indicate a
pathogenic role for plasma cell-secreted myelin-speciﬁc antibodies.
Alternatively, although not mutually exclusive, accelerated EAE severity
may reﬂect a pathogenic role formyelin-speciﬁc B cells in processing and
presentation of myelin antigen to encephalitogenic T cells.
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As EAE induced by active immunization with self-antigen or
passive transfer of encephalitogenic T cells is unlikely to ﬁttingly
reﬂect MS pathogenesis characterized by chronic inﬂammation and
the lack of an apparent disease trigger, recent efforts have been
focused on developing EAE models which do not require their active
induction. All of these models have in common, that B cells, T cells, or
both are genetically engineered to recognize CNS antigens at a higher
frequency than mouse strains susceptible to induced EAE. While it is
debatable whether “spontaneously” occurring EAE in these transgenic
mice reﬂects MS pathogenesis more closely, these models undoubt-
edly provide an excellent tool to study the interaction of self-reactive
T cells, B cells, and antibodies.
One of the ﬁrst of these spontaneous EAE models has been
described after the above-mentioned transgenic mice, in which a high
frequency of B cells express a pathogenic antibody againstMOG (MOG
B-cell knockin), were crossed onto a line of transgenic mice in which a
majority of T cells responds to MOG p35–55. While it needs to be
noted that approximately 40% of these single-transgenic MOG T-cell
receptor transgenic mice were already affected by optic neuritis, they
rarely revealed symptoms of spontaneous paralysis [100,101]. In
contrast, in the double-transgenic mice containing in addition a high
frequency of MOG recognizing B cells, approximately 60% spontane-
ously developed a severe form of EAE with meningeal and
parenchymal lesions [100,102]. Interestingly, inﬂammatory lesions
remained restricted to the spinal cord and optic nerves, not unlike in
NMO or Devic's syndrome, which selectively affects optic nerves and
spinal cord, but spares the brain [103,104]. In NMO, however,
accumulating evidence suggests that a serum antibody against Aqp-
4 may have the central pathogenic impact. It is thus unlikely that the
selective appearance of spinal and optic nerve inﬂammatory lesions in
B-cell/T-cell double-transgenic mice indicates a true parallel to NMO
pathogenesis. Nevertheless, this model suggests that the myelin
speciﬁcity of B cells and T cells is, in principle, sufﬁcient to trigger
spontaneous CNS autoimmune disease. It remains to be determined in
further studies whether this spontaneous model primarily relates to
the abundance of myelin-speciﬁc antibodies or, alternatively, to the
fact that MOG-speciﬁc B cells serve as efﬁcient APCs for the activation
of MOG p35–55-speciﬁc T cells in these mice.
Another recently described spontaneous EAE model apparently
also relies on the interaction of myelin-speciﬁc B cells and/or
antibodies and T cells [105]. In this model, T cells are genetically
engineered to recognize MOG peptide 92–106 resulting in
spontaneous relapsing–remitting EAE on the otherwise wild-type
SJL/J background. Backcrossing these T-cell transgenic mice to a line
expressing the MOG binding antibody 8.18-C.5 on B cells led to an
earlier onset of an even more severe spontaneous EAE disease
course. In single T-cell transgenic mice with later disease onset,
myelin-speciﬁc B cells were shown to be recruited and expanded
from the endogenous repertoire, which results in the development
of pathogenic anti-MOG antibody titers comparable to those in
wild-type mice actively immunized with rMOG. In both single- and
double-transgenic mice, anti-CD20-mediated B-cell depletion could
abrogate spontaneous EAE development, proving that endogenously
recruited or transgenically engineered myelin-speciﬁc B cells or
antibodies were indeed mandatory for initiation of spontaneous disease.
Counterintuitively,myelin-speciﬁcB cells obtained fromthesemicewere,
however, unable to recognize the transgenic T-cell determinant 92–106.
Further, spontaneous disease was not observed when MOG p92-106
T-cell receptor transgenic mice were crossed onto a MOG-deﬁcient
background. Collectively, these ﬁndings indicate that in this model,
activation of abundant MOG p92–106-speciﬁc T cells requires prior
encounter of B cells with endogenous MOG. Similar to the spontaneous
EAE model described in the paragraph above, it remains yet unclear
whether spontaneous CNS autoimmune disease in these mice reliesprimarily on cellular function of myelin-speciﬁc B cells or B-cell-derived
myelin-speciﬁc antibodies.4. Conclusions
Several lines of evidence indicate that B cells, plasma cells, and, in
particular, antibodies contribute to development and progression ofMS.
The analysis of B cells and B-cell-derived cells within CNS lesions, but
also within the CSF, revealed a very restricted clonal expansion of
particular B-cell entities. Together with signs of hypermutation, these
ﬁndings are indicative of a local activation and maturation of these B
cells within the CNS itself. A recent study comparing the CSF IgG
proteome with the IgG transcriptome of cells from the B-cell lineage
within the CNS demonstrated a substantial overlap between both
compartments. These ﬁndings suggest that commonly found OCBs in
the CSF of MS patients may indeed be produced by successors of B cells
activated within the CNS itself. The central question remains, however,
whether such local activation and consequential production of the
respective antibodies derives fromB-cell antigen recognitionwithin the
CNS. While in NMO, the pathogenic antibody response could be
identiﬁed to be directed against astrocytic Aqp-4, to date, no conclusive
understanding exists on possible CNS target antigens against which the
antibody response may be raised in MS. Empirical support for a
pathogenic role of antibodies derives from the therapeutic approach of
plasma exchange, whichwas found to be beneﬁcial in a subgroup of MS
patients with severe therapy-refractory relapses and antibody deposi-
tion within inﬂammatory CNS lesions. These data suggest that, in a
subgroup of patients, peripherally produced CNS-directed antibodies
may indeed contribute to MS pathogenesis.
Besides these ﬁndings in MS patients, several observations derived
from experimental CNS autoimmunity suggest that B cells and CNS-
reactive antibodies contribute in a pathogenic manner. B cells, plasma
cells, and antibodies accumulate in areas of myelin breakdown in EAE
not unlike inﬂammatory CNS lesions in MS patients. EAE induction by
immunization with myelin protein involves B-cell activation leading
to development of myelin-speciﬁc antibodies. Transfer of antibodies
against myelin into mice with ongoing EAE enhances CNS demyelin-
ation and exacerbates clinical EAE symptoms, suggesting that myelin-
speciﬁc antibodies accelerate EAE pathogenesis. Further, such evi-
dence derives from mice that are genetically engineered to express a
myelin-reactive B-cell receptor on a high percentage of B cells and to
secrete the corresponding antibody by B-cell-derived plasma cells.
Immunization of these mice revealed an exacerbation of EAE severity
with augmented CNS inﬂammation and demyelination. When these
B-cell receptor knock-in mice were crossed with transgenic mice in
which a majority of T cells also recognizes myelin antigen, the
resulting mouse line developed spontaneous EAE with a high disease
incidence. Another spontaneous EAE model similarly demonstrated
that myelin-recognizing B cells and/or antibodies are required for EAE
induction in transgenic mice with a high frequency of myelin-speciﬁc
T cells. Taken together, these experimental ﬁndings suggest that
myelin-reactive B cells and antibodies—although not required for
active induction of EAE—enhance CNS pathology in conventional EAE
and support myelin-reactive T cells to induce disease in recently
developed spontaneous EAE models.References
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